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WS9.5 Saline at lower tonicity in cystic ﬁbrosis (SALTI-CF) trial −
A randomised, controlled trial comparing 0.9% v 3% v 6%
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The ideal concentration of hypertonic saline (HS) in people with cystic ﬁbrosis (CF)
is unknown. Regular use of HS between 6−7% improves lung function [1,2], however
these concentrations are not always tolerable [3]. Increasing HS concentration between
3−12% has a greater effect on mucus clearance, though also reduces tolerability [4].
Clinically, many CF patients report HS concentrations less than 6% to be more tolerable,
yet the regular use of lower concentrations of HS has not been examined.
Aims: Evaluate the relative efﬁcacy and tolerability of 0.9% v 3% v 6% saline nebulised
twice daily with an eFlow® rapid.
Methods: Randomised, blinded, placebo-controlled, parallel-group, multi-centre study
where subjects inhaled 4mL of 0.9% or 3% or 6% saline twice daily for 16 weeks. Trial
saline was taste-masked with 0.25mg/mL quinine sulphate. Participants had conﬁrmed
CF, aged 6 years and FEV1 >20% predicted. Participants were excluded if they were
taking mannitol, had a recent pulmonary exacerbation and/or unstable lung function.
Outcomes: Primary outcome was FEV1. Secondary outcomes were: FVC and FEF25−75,
quality of life, exercise capacity, acquisition or loss of bacterial organisms in expec-
torated sputum, tolerability of nebulised saline, pulmonary exacerbations and adverse
events.
Results: 140 participants have enrolled and begun the study with the last participant due
to complete the study in March 2013. Results will be presented at the 2013 European
CF Conference for the ﬁrst time.
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WS9.6 Cystic ﬁbrosis-related postural and baropodometric changes:
A comparison with healthy individuals
M.V. Donadio1, C.S. Schindel1, P.X. Hommerding2, D.A. Melo1, R.R. Batista1,
P.J. Marostica3. 1PUCRS, Porto Alegre, Brazil; 2UNIFRA, Santa Maria, Brazil;
3UFRGS, Porto Alegre, Brazil
Objectives: Few studies have addressed the postural imbalance as a consequence of
pulmonary and thoracic disorders in cystic ﬁbrosis (CF). The aim of present study
was to compare postural and baropodometric evaluations between CF and healthy
children and adolescents.
Methods: We performed a cross-sectional study evaluating 34 children and ado-
lescents with CF, aged 6 to 20 years, as well as 34 age, height and weight matched
healthy control subjects. Patients were recruited in the CF outpatient service after
anthropometric and lung function data were collected. Healthy individuals were
selected from private and public schools after a respiratory health questionnaire
was ﬁlled out. In both groups, individuals were submitted to postural evaluation
trough digital photos in 3 different plans using the SAPO software and to dynamic
and static baropodometric test using the Footwork software. Data was compared
using a student t test. All parents or legal guardians signed a consent form prior
to data collection. In total, 68 individuals (41.2% female) were studied with a
mean age of 12.8±3.3. Signiﬁcant differences in the postural assessment were
identiﬁed in the head inclination (p = 0.001), scapular inclination (p = 0.01), pelvic
inclination (p = 0.001), cervical lordosis (p = 0.001), thoracic kyphosis (p = 0.05) and
lateral thoracic distance (p = 0.002). No signiﬁcant differences were found in the
baropodometric analysis.
Conclusion: Our results show that CF children and adolescents present important
postural abnormalities when compared to healthy individuals. Objective postural
evaluation may help professionals to quantify, follow and treat postural disorders
in these patients.
